Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Detailed, Expanded Analysis (US) Current Treatment: Physician Insights

Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal (IVT) pharmacotherapy approvals across different drug classes in the United States and Europe since 2011. Although laser photocoagulation has long been the standard of care for patients with the most advanced stages of DR, recent clinical trial results indicate that IVT pharmacotherapy injections may be effective treatments for this broader patient population as well (e.g., the CLARITY, PANORAMA, Protocol W trials), and IVT anti-vascular endothelial growth factor (VEGF) drugs have progressively received approval for all forms of DR. The Diabetic Retinopathy/Diabetic Macular Edema | Current Treatment Overview provides a synopsis of current treatment goals, key therapies, and medical practice in the U.S. and EU5 markets for DR and DME. The Diabetic Retinopathy/Diabetic Macular Edema | Current Treatment | US detailed, expanded analysis offers a snapshot of how ophthalmologists in the United States are currently treating DR and DME patients, with a particular focus on the use of IVT VEGF inhibitors and IVT corticosteroid implants, as well as insight into the factors driving such prescribing habits.

Table of contents

  • Diabetic Macular Edema / Diabetic Retinopathy - Current Treatment - Detailed, Expanded Analysis (US) Current Treatment: Physician Insights
    • Current Treatment Diabetic Retinopathy-Diabetic Macular Edema US-September 2021

launch Related Market Assessment Reports